Tarsus Raises $134.8M Public Offering
Tarsus Pharmaceuticals Inc. closed an upsized $134.8 million public offering this month. The Irvine-based biopharmaceutical company plans to use net proceeds to boost commercialization of its eyedrop Xdemvy in the U.S., as well as develop treatments for other diseases such as ocular rosacea and Lyme disease, according to a Feb. Read More